Clinical Trial Update: Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of ABT-126 in stable subjects with schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ABT-126

Snippet

Sponsor: Abbott | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED